Skip to content

Loading your page…

Active substance · J05AB17

Brincidofovir

On 2 registers4 medicines2 companies

See every medicineAsk Osler about it

Classification

Anatomical main groupJAnti-infectives for systemic use
Therapeutic subgroupJ05
Pharmacological subgroupJ05A
Chemical subgroupJ05AB
Chemical substanceJ05AB17Brincidofovir

Where it is registered

Each register with its number of medicines and a few of them.

Canada
Health Canada · 2 medicines
- Tembexa10 MG / ML · Suspension · Emergent Biodefense Operations Lansing LLC
- Tembexa100 MG · Tablet · Emergent Biodefense Operations Lansing LLC
United States
FDA · 2 medicines
- Tembexa100MG · tablet · Emergent Biodefense
- Tembexa10MG/ML · suspension · Emergent Biodefense

All medicines with Brincidofovir

Every register, a page at a time. Strengths and packs are on each medicine’s page.

3 results

Medicine	Register	Strength	Form	Status	Holder
Tembexa	United States	10MG/ML	suspension	Marketed	Emergent Biodefense
Tembexa	United States	100MG	tablet	Marketed	Emergent Biodefense
Cidofovir	United States	375MG BASE/5ML	solution	Marketed	Mylan Institutional

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.